$ETON SEC Filings

Filed On	Filing
14 Oct 2026	8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
06 Oct 2026	Form 4: Krempa David, Chief Business Officer Received 10,522 shares by exercise or conversion · Sold 4,166 shares ($229K)
06 Oct 2026	144
28 Sep 2026	8-K: Other Events Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States
31 Aug 2026	Form 4/A: Maier Paul V, Director Received 62,500 shares by exercise or conversion ($280K) · Sold 50,000 shares ($2.95M) · Acquired 12,500 Employee Stock Option (Option Exercise/Conversion)
28 Aug 2026	144
28 Aug 2026	Form 4: Maier Paul V, Director Received 50,000 shares by exercise or conversion ($189K) · Sold 50,000 shares ($2.95M)
24 Aug 2026	Form 4: Krempa David, Chief Business Officer Received 25,000 shares by exercise or conversion ($183K) · Sold 25,000 shares ($1.63M)
24 Aug 2026	144
20 Aug 2026	Form 4: Brynjelsen Sean, Director Sold 8,978 shares ($562K) · Sold 91,022 shares ($5.53M)
20 Aug 2026	144/A
19 Aug 2026	144
13 Aug 2026	FORM 10-Q
13 Aug 2026	8-K: Results of Operations and Financial Condition
12 Aug 2026	Form 3: Radosavljevic Danka, Chief Operating Officer Holds 22,473 shares of Common Stock
05 Aug 2026	8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets
04 Aug 2026	Form 4: Casamento Charles J, Director Granted 10,000 Common Stock
04 Aug 2026	Form 4: Matthews Judith M., Chief Financial Officer Granted 32,246 Common Stock
04 Aug 2026	Form 4: Erdogan-Trinkaus Ipek, Chief Commercial Officer Granted 80,000 Common Stock
04 Aug 2026	Form 4: Brynjelsen Sean, Director Granted 128,985 Common Stock

Comments